Pharma channel feed

As gener­ic com­pe­ti­tion stut­ter sales of top on­col­o­gy drugs, Roche se­cures speedy re­view for pair of ex­per­i­men­tal can­cer of­fer­ings

7 years ago

Trop­i­cal dis­ease PRV fix didn’t stop No­var­tis from win­ning an­oth­er

7 years ago

FDA doc re­veals agency charged Im­munomedics with da­ta in­tegri­ty breach af­ter Au­gust plant in­spec­tion

7 years ago

Ap­pro­pri­a­tions bill would give FDA $269M boost over FY2018 bud­get

7 years ago

Ra­maswamy's Ax­o­vant whips up a CNS spin­off with a $530M deal and a syn­di­cate of sup­port­ers

7 years ago
Startups

DBV es­ti­mates peanut al­ler­gy drug sub­mis­sion in Q3, but it may be too lit­tle too late in race with Aim­mune

7 years ago

Do­nat­ed glob­al­ly since 2005, No­var­tis' flat­worm treat­ment Egat­en wins FDA nod — and a PRV

7 years ago

The $100M biotech club: Who's in, and what’s it take to join the top-per­form­ing group of bio­phar­mas?

7 years ago

As drug­mak­ers seek ways to elude IL-2 flaws, Clin­i­gen se­cures the full rights to orig­i­nal trou­bled IL-2 drug Pro­leukin

7 years ago

House com­mit­tee weighs drug pric­ing pro­pos­als

7 years ago

FDA ex­perts of­fer a big thumbs up for J&J’s flawed ap­pli­ca­tion for ke­t­a­mine-based de­pres­sion drug — but tri­al fail­ures, safe­ty ques­tions spur con­cerns

7 years ago

The high rollers: The top 20 block­buster bio­phar­ma deals of the past decade

7 years ago

FDA tar­gets prod­ucts false­ly claim­ing to treat Alzheimer’s dis­ease

7 years ago

FDA promis­es speedy re­view on mov­ing Mer­ck­'s Keytru­da up as first-line head and neck can­cer ther­a­py

7 years ago

Top 20 biotech deals: 2019 deal­mak­ing gets off to a roar­ing start, build­ing on a record amount for '18

7 years ago

Ab­b­Vie jumps in­to the fren­zied race for a BC­MA/CD3 bis­pe­cif­ic tar­get­ing mul­ti­ple myelo­ma. Teneo­bio who?

7 years ago

Re­gen­eron, Sanofi slash Pralu­ent list price mir­ror­ing Repatha dis­count

7 years ago

Macro­mol­e­cules in a pill? Tor­toise-in­spired cap­sule of­fers hope in an ear­ly test de­liv­er­ing in­sulin in­to stom­ach wall

7 years ago

Should J&J win an OK for a flawed de­pres­sion drug af­ter no­table tri­al fail­ures? FDA re­view of­fers a path for­ward

7 years ago

As mag­ni­tude and fre­quen­cy of drug price hikes thaw, Ex­press Scripts re­ports low­est in­crease in spend­ing by com­mer­cial plans in 25 years

7 years ago

Bur­nish­ing its rare dis­ease drug am­bi­tions, Sanofi picks up fast FDA OK for Ca­blivi — cour­tesy of a $4.8B buy­out

7 years ago

Capri­cor to re­sume dos­ing in DMD tri­al — but scarce re­sources force com­pa­ny to pause en­roll­ment, cut jobs

7 years ago

To tack­le su­per­bug scourge and re­vive R&D, in­cen­tivize FDA an­tibi­ot­ic ap­provals — drug­mak­ers, health groups urge US law­mak­ers

7 years ago
R&D

Say what? Trump de­clares a big vic­to­ry in the war on drug prices — for De­cem­ber, any­how

7 years ago
First page Previous page 276277278279280281282 Next page Last page
A service from the Financial Times